Earlier this year, Zambia launched the use of an injectable HIV prevention drug that blocks the HIV replication process and almost eliminates a person’s chance of contracting HIV, according to experts. Zambia is the first country in sub-Saharan Africa to offer the pre-exposure prophylaxis or PrEP injectable, also known as long-acting cabotegravir CAB-LA. VOA’s Linord Moudou spoke with Lackeby Kawanga, Director of Technical Services for global health care nonprofit JSI, for the USAID DISCOVER project in Zambia.